Study Results from Institute for Clinical and Economic Review in the Area of Managed Care Reported (Informing the US Medicare drug price negotiation for Trelegy Ellipta and Breo Ellipta: Evaluating the impact of real-world evidence): Managed Care

2026 APR 07 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- A new study on Managed Care is now available. According to news originating from Boston, Massachusetts, by NewsRx correspondents, research stated, “The Institute for Clinical and Economic Review (ICER) conducted a special assessment of Trelegy Ellipta and Breo Ellipta for chronic obstructive pulmonary disease (COPD) to inform the CMS drug price negotiation process. In this manuscript, we examine the type, quality, and impact of the observational evidence included.”

Our news journalists obtained a quote from the research from Institute for Clinical and Economic Review, “We described the type of observational evidence used in ICER’s assessment with a primary focus on adherence and persistence data. Risk of bias was assessed using the ROBINS-I. Observational data included in ICER’s review primarily informed the assessment of differential adherence and persistence between single and multiple inhaler products. The majority of studies were real-world evidence (RWE), utilizing claims or electronic health record data, and were deemed to be at moderate or severe risk of bias. RWE reported that Trelegy Ellipta and Breo Ellipta were associated with greater adherence and persistence compared to generic multiple-inhaler or multiple-daily-dosing alternatives. Persistence data were critical for differentiating between products in the cost-effectiveness analysis; however, persistence was based on prescription refills which is an imperfect measure of treatment continuation. RWE played a critical role in evaluating the comparative clinical and cost-effectiveness of Trelegy Ellipta and Breo Ellipta to inform CMS drug price negotiations. Differences in persistence informed differential pricing to generic multiple-inhaler or multiple-daily-dosing alternatives, demonstrating how data collected outside of clinical trials can inform value assessments.”

According to the news editors, the research concluded: “However, RWE limitations and the lack of evidence linking adherence or persistence to clinical outcomes highlight the need for future research.”

This research has been peer-reviewed.

For more information on this research see: Informing the US Medicare drug price negotiation for Trelegy Ellipta and Breo Ellipta: Evaluating the impact of real-world evidence. Value In Health, 2026. Value In Health can be contacted at: Elsevier Science Inc, Ste 800, 230 Park Ave, New York, NY 10169, USA. (Elsevier - www.elsevier.com; Value In Health - http://www.journals.elsevier.com/value-in-health/)

The news correspondents report that additional information may be obtained from Marina Richardson, Institute for Clinical and Economic Review (ICER), Boston, MA, United States. Additional authors for this research include Abigail C. Wright, Shahariar Mohammed Fahim, Jeffrey A. Tice, Kangho Suh, Josh J. Carlson and David M. Rind.

The publisher’s contact information for the journal Value In Health is: Elsevier Science Inc, Ste 800, 230 Park Ave, New York, NY 10169, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)